Jump to content

Truveta

Add links
From Wikipedia, the free encyclopedia
Truveta, Inc.
Company typePrivate
IndustryHealth technology
Founded2020
HeadquartersBellevue, Washington, U.S.A.
Key people
Terry Myerson, CEO
Websitewww.truveta.com

Truveta, Inc. is an American health data and analytics company headquartered in Bellevue, Washington and owned and governed by 30 U.S. health systems.[1]

Truveta was established in 2020 by Providence, Advocate Health, Tenet Healthcare, and Trinity Health. The company was publicly introduced in February 2021 with fourteen founding health system members.[2] As of 2025, Truveta includes 30 U.S. health systems as members.[3] Truveta provides de-identified electronic health record data for more than 120 million U.S. patients.[3][2]

History

[edit]

Truveta was formed in September 2020 by a group of U.S. health systems seeking to develop a shared data resource.[4] The company was publicly introduced in February 2021, with initial participating systems including AdventHealth, Advocate Aurora Health, Baptist Health of Northeast Florida, Bon Secours Mercy Health, CommonSpirit Health, Hawaii Pacific Health, Henry Ford Health System, Memorial Hermann Health System, Northwell Health, Novant Health, Providence, Sentara Healthcare, Tenet Health, and Trinity Health.[2]

In 2021, Truveta entered a partnership with Microsoft to support its cloud and artificial intelligence infrastructure.[5] Later that year, the company released its first data platform and shared initial analytic findings.[6]

In 2022, Pfizer became Truveta's first life sciences customer,[7][8] and Boston Scientific also began using the company's data platform.[9] In 2023, Truveta introduced the Truveta Language Model, a multimodal large-language model designed to structure clinical data from electronic health records.[10][11] In 2025, the company launched the Truveta Genome Project in collaboration with participating health systems, Regeneron, Illumina, and Microsoft, alongside raising $320 million in Series C funding.[12][13]

Research using Truveta data

[edit]

Studies using Truveta data have been published in peer-reviewed journals across infectious diseases, cardiology, pediatrics, gastroenterology, medical informatics, health services research, and population health.

Infectious diseases and public health

[edit]

A 2023 study published in Vaccine assessed the risk of COVID-19 breakthrough infection and hospitalization among individuals with comorbidities using data from U.S. health-system records, including those from Truveta-affiliated systems.[14] A 2023 study in Frontiers in Public Health evaluated racial inequalities in COVID-19 treatment and in-hospital length of stay in the United States over time, using data derived from large health-system datasets including those affiliated with Truveta.[15] A 2025 study published in the American Journal of Preventive Medicine analyzed trends in syphilis incidence among U.S. adults from January 2017 to October 2024 using Truveta data.[16] Another 2025 study in Sexually Transmitted Diseases assessed the need for creating ICD-10 codes to improve monitoring of doxycycline postexposure prophylaxis prescriptions in the United States.[17]

Cardiology and cardiovascular outcomes

[edit]

Truveta data have been used in several cardiovascular studies. A real-world, big-data analysis in the Journal of the Society for Cardiovascular Angiography & Interventions[18] compared ultrasound-assisted catheter-directed therapy (USCDT) with medical therapy for pulmonary embolism (the REAL-PE study), based on data drawn from Truveta-affiliated health systems.[19] A subsequent 2024 analysis in the same journal reported additional real-world findings on USCDT versus standard medical therapy for pulmonary embolism using U.S. health-system records, including those from Truveta-affiliated systems.[20] A 2024 cohort study in JACC: Heart Failure evaluated decongestion strategies in patients hospitalized for heart failure using a large community-based dataset including records from Truveta-affiliated health systems.[21] In 2025, a real-world analysis in the Journal of Cardiac Failure evaluated survival outcomes associated with cardiac contractility modulation devices, using cardiac resynchronization therapy data to validate methodological approaches with large U.S. health-system records, including those from Truveta-affiliated systems.[22]

Pediatrics

[edit]

In pediatrics, a 2023 time-series study published in JAMA Pediatrics examined first-time pediatric speech delay incidence from 2018 to 2022 using data from U.S. health systems, including those affiliated with Truveta.[23] A 2025 study in Pediatrics Open Science examined changes in pediatric obesity treatment practices in the United States following updated guidelines from the American Academy of Pediatrics, using data from large health-system records, including those affiliated with Truveta.[24]

Pharmacoepidemiology and therapeutics

[edit]

A 2023 study in JAMA Network Open examined changes in prescribing patterns of oral minoxidil for hair loss after media attention, using prescription data from U.S. health-system records, including those affiliated with Truveta.[25] A 2025 study, also in JAMA Network Open, examined patterns of discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among U.S. adults with overweight or obesity using Truveta data.[26] In 2024, a study in JAMA Internal Medicine compared the effectiveness of semaglutide versus tirzepatide for weight loss in adults with overweight or obesity, using data from Truveta-affiliated health systems.[27]

Gastroenterology and cancer screening

[edit]

A 2024 study published in The American Journal of Gastroenterology examined real-world adherence to repeat stool-based colorectal cancer screening among individuals at average risk, using fecal immunochemical tests (FIT) and multi-target stool DNA tests (mt-sDNA). The authors analyzed patterns of repeat testing and evaluated factors associated with adherence over time.[28]

Nephrology and procedural outcomes

[edit]

A 2025 retrospective evaluation in The International Journal of Artificial Organs analyzed design features, associated risks, and usage trends of non-tunneled hemodialysis catheters, comparing dual- and triple-lumen devices based on real-world data.[29] Another 2025 study, published in Journal of Endourology / Urology & Nephrology Clinics, compared postoperative infection rates for patients using a single-use ureteroscope with real-time intrarenal pressure monitoring versus other single-use ureteroscopes in clinical practice, using large health-system datasets.[30]

Medical informatics, AI, and multimodal modeling

[edit]

Several studies have focused on data standards and artificial intelligence using Truveta data. A 2023 preprint titled Truveta Mapper: A Zero-shot Ontology Alignment Framework presented a methodology for aligning biomedical ontologies using zero-shot learning, as a tool that could support data interoperability for health systems.[31] A 2025 study published in Studies in Health Technology and Informatics explored structured large language model (LLM) augmentation for clinical information extraction, assessing its performance and potential for healthcare data analysis.[32] In 2025, a study in Radiology Advances developed "XComposition", a multimodal deep-learning model that uses chest radiographs and clinical data to estimate body composition, as an application of large health-system data for medical imaging research.[33]

References

[edit]
  1. ^ "Truveta data expands beyond EHR". Yahoo Finance. 2021-02-24.
  2. ^ a b c Boss, Dina; Tozzi, John (2021-02-11). "Startup Truveta links U.S. health systems to share patient data". Bloomberg.
  3. ^ a b Fox, Andrea (15 January 2025). "Truveta and 30 health systems increase genomic sequencing goal". Healthcare IT News. Retrieved 11 December 2025.
  4. ^ Mathews, Anna Wilde (2021-02-11). "Major Hospitals Form Company to Capitalize on Their Troves of Health Data". The Wall Street Journal. Retrieved 2025-12-03.
  5. ^ Miliard, Mike (2021-09-30). "Truveta, Microsoft form cloud AI partnership with strategic investment". Healthcare IT News. Retrieved 2025-12-03.
  6. ^ Schubert, Charlotte (2021-10-11). "Healthcare-data startup Truveta showcases new platform, now raised close to $200M". GeekWire. Retrieved 2025-12-03.
  7. ^ Wu, Lei Lei (2022-06-21). "Big data meets Big Pharma: Pfizer buys real-time patient results in collaboration with Truveta". Endpoints News. Retrieved 2025-12-03.
  8. ^ Schubert, Charlotte (2022-06-21). "Health data company Truveta to partner with Pfizer on monitoring COVID vaccines and therapies". GeekWire. Retrieved 2025-12-03.
  9. ^ Diller, Wendy (2022-11-17). "Truveta and Boston Scientific Strive for the Ultimate in Data Sharing: Speed, Accuracy, and Privacy". MedTech Strategist. Retrieved 2025-12-03.
  10. ^ Lampton, Ellie (2023-04-12). "Announcing the Truveta Language Model". Truveta. Retrieved 2025-12-03.
  11. ^ Schubert, Charlotte (2023-04-13). "This AI understands doctors' notes: Truveta's new model finds meaning in messy healthcare data". GeekWire. Retrieved 2025-12-03.
  12. ^ Leake, Lindsey (2025-01-16). "Truveta genome project teams with Regeneron and Illumina to sequence US health-system patients". Fortune. Retrieved 2025-12-03.
  13. ^ Niasse, Amina (2025-01-13). "Truveta sells stakes in Regeneron-Illumina deal to help build genetic database". Reuters. Retrieved 2025-12-03.
  14. ^ Smits, Peter D.; Gratzl, Samuel; Simonov, Michael; Nachimuthu, Senthil K.; Goodwin Cartwright, Brianna M.; Wang, Michael D.; Baker, Charlotte; Rodriguez, Patricia; Bogiages, Mackenzie; Althouse, Benjamin M.; Stucky, Nicholas L. (2023-03-29). "Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities". Vaccine. 41 (15): 2447–2455. doi:10.1016/j.vaccine.2023.02.038. PMC 9933320. PMID 36803895.
  15. ^ Althouse, Benjamin M.; Baker, Charlotte; Smits, Peter D.; Gratz, Samuel; Lee, Ryan H.; Goodwin Cartwright, Brianna M.; Simonov, Michael; Wang, Michael D.; Stucky, Nicholas L. (2023-01-10). "Racial inequality in COVID-treatment and in-hospital length of stay in the US over time". Frontiers in Public Health. 10 1074775. Bibcode:2023FrPH...1074775A. doi:10.3389/fpubh.2022.1074775. PMC 9876573. PMID 36711416.
  16. ^ Do, Duy; Rodriguez, Patricia J.; Gratzl, Samuel; Goodwin Cartwright, Brianna M.; Baker, Charlotte; Stucky, Nicholas L. (2025-04-01). "Trends in Incidence of Syphilis Among US Adults from January 2017 to October 2024". American Journal of Preventive Medicine. doi:10.1016/j.amepre.2025.03.008. PMID 40185421. Retrieved 2025-12-03.
  17. ^ Tao, Guoyu; He, Larry; Patel, Chirag; Papp, John; Barbee, Lindley A. (2025-09-18). "Assessing the need for creating ICD-10 codes to enhance monitoring of doxycycline postexposure prophylaxis prescriptions in the United States". Sexually Transmitted Diseases. doi:10.1097/OLQ.0000000000002245. PMID 40965055. Retrieved 2025-12-03.
  18. ^ "Home Page: Journal of the Society for Cardiovascular Angiography & Interventions". www.jscai.org. Retrieved Dec 9, 2025.
  19. ^ Monteleone, Peter; Ahern, Ryan A.; Banerjee, Subhash; Desai, Kush R.; Kadian-Dodov, Daniella; Webber, Emily; Omidvar, Sally; Troy, Patrick; Parikh, Sahil A. (2023-10-24). "Modern Treatment of Pulmonary Embolism (USCDT vs MT): Results From a Real-World, Big Data Analysis (REAL-PE)". Journal of the Society for Cardiovascular Angiography & Interventions. 3 (1) 101192. doi:10.1016/j.jscai.2023.101192. PMC 11308131. PMID 39131982. Retrieved 2025-12-03.
  20. ^ Monteleone, Peter; Ahern, Ryan A.; Banerjee, Subhash; Desai, Kush R.; Kadian-Dodov, Daniella; Webber, Emily; Omidvar, Sally; Troy, Patrick; Parikh, Sahil A. (2024-01-01). "Modern Treatment of Pulmonary Embolism (USCDT vs MT): Results From a Real-World, Big Data Analysis (REAL-PE)". Journal of the Society for Cardiovascular Angiography & Interventions. 3 (1) 101192. doi:10.1016/j.jscai.2023.101192. PMC 11308131. Retrieved 2025-12-03.
  21. ^ Zheng, Jimmy; Ambrosy, Andrew P.; Bhatt, Ankeet S.; Collins, Sean P.; Flint, Kelsey M.; Fonarow, Gregg C.; Fudim, Marat; Greene, Stephen J.; Lala, Anuradha; Testani, Jeffrey M.; Varshney, Anubodh S.; Wi, Ryan S.K.; Sandhu, Alexander T. (2024-04-07). "Contemporary Decongestion Strategies in Patients Hospitalized for Heart Failure: A National Community-Based Cohort Study". JACC: Heart Failure. 12 (8). doi:10.1016/j.jchf.2024.04.002. PMID 38678466. Retrieved 2025-12-03.
  22. ^ Sauer, Andrew J.; Hass, Ryan; Cranke, Gary; Burkhoff, Daniel; Rao, Ishu (2025-09-01). "Real-World Survival Outcomes With Cardiac Contractility Modulation: Methodological Validation Using Cardiac Resynchronization Therapy Data". Journal of Cardiac Failure. 31 (9): 1490–1492. doi:10.1016/j.cardfail.2025.08.009. PMC 12661499. PMID 41233031. Retrieved 2025-12-03.
  23. ^ Goodwin Cartwright, Brianna M.; Smits, Peter D.; Stewart, Sarah (2023-12-04). "Time-Series Analysis of First-Time Pediatric Speech Delays From 2018 to 2022". JAMA Pediatrics. 178 (2): 193–195. doi:10.1001/jamapediatrics.2023.5226. PMC 10696512. PMID 38048098.
  24. ^ Rodriguez, Patricia J.; Do, Duy; Gratzl, Samuel; Goodwin-Cartwright, Brianna M.; Stucky, Nicholas L.; Wright, Davene R. (2025-08-01). "Shifts in US Pediatric Obesity Treatment After the AAP Guidelines". Pediatrics Open Science. 1 (3): 1–12. doi:10.1542/pedsos.2025-000623. Retrieved 2025-12-03.
  25. ^ Goodwin Cartwright, Brianna M.; Wang, Michael; Rodriguez, Patricia; Stewart, Sarah; Worsham, Christopher M.; Stucky, Nick; Jena, Anupam B. (2023-05-09). "Changes in Minoxidil Prescribing After Media Attention About Oral Use for Hair Loss". JAMA Network Open. 6 (5): e2312477. doi:10.1001/jamanetworkopen.2023.12477. PMC 10170338. PMID 37159202.
  26. ^ Rodriguez, Patricia J.; Zhang, Vincent; Gratzl, Samuel (2025-01-31). "Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity". JAMA Network Open. 8 (1): e2457349. doi:10.1001/jamanetworkopen.2024.57349. PMC 11786232. PMID 39888616.
  27. ^ Rodriguez, Patricia J.; Goodwin Cartwright, Brianna M.; Gratzl, Samuel (2024-07-08). "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity". JAMA Internal Medicine. 184 (9): 1056–1064. doi:10.1001/jamainternmed.2024.2525. PMC 11231910. PMID 38976257.
  28. ^ Shaukat, Aasma; Liao, Jiemin; Saha, Jayati; Forbes, Shaun P.; Watkins, Angela; Zhang, Nicole J.; Raymond, Victoria M.; Das, Amarendra; Eagle, Craig; Talasaz, AmirAli (2024-10-01). "S375 Real-World Adherence to Repeat Testing for Stool-Based Non-Invasive Colorectal Cancer Screening Tests Among Individuals With Average Risk". The American Journal of Gastroenterology. 119 (10S): S265 – S266. doi:10.14309/01.ajg.0001030868.43296.05. Retrieved 2025-12-03.
  29. ^ Miller, George; Zabaleta, Isabella; Ogujiofor, Kingsley; Fatima, Rukhaiya; Albrecht, Emma; Warden, Madalyn (2025-07-02). "Design features, associated risks, and usage trends of non-tunneled hemodialysis catheters: A retrospective evaluation of dual and triple lumen devices". The International Journal of Artificial Organs. doi:10.1177/11297298251352470. PMID 40605326.
  30. ^ Bhojani, Naeem; Morris, Kathryn; White, Jenifer; Rojanasarot, Sirikan; Tran, Emma D.; Monga, Manoj (2025-09-16). "Post-operative infection with a single-use ureteroscope with real-time intrarenal pressure monitoring vs. all other single-use ureteroscopes". Journal of Endourology / Urology & Nephrology Clinics. 22 (10): 1135–1143. doi:10.1080/17434440.2025.2557403. PMID 40908713. Retrieved 2025-12-03.
  31. ^ Amir, Mariyam; Baruah, Murchana; Eslamialishah, Mahsa; Ehsani, Sina; Bahramali, Alireza; Naddaf-sh, Sadra; Zarandioon, Saman (2023-01-24). "Truveta Mapper: A Zero-shot Ontology Alignment Framework". arXiv. arXiv:2301.09767. S2CID 256194088.
  32. ^ Wei, Ying; Li, Qi; Pillai, Jay (2025-08-07). "Structured LLM Augmentation for Clinical Information Extraction". Studies in Health Technology and Informatics. 329: 971–976. doi:10.3233/SHTI250984. ISBN 978-1-64368-608-0. PMID 40776002.
  33. ^ Alipour, Ehsan; Gratzl, Samuel; Algohary, Ahmad; Lin, Hao; Bapat, Manoj; Do, Duy; Baker, Charlotte; Rodriguez, Tricia; Goodwin Cartwright, Brianna M.; Hadlock, Jennifer; Tarczy-Hornoch, Peter; Oka, Anand; Stucky, Nicholas L. (2025-10-03). "XComposition: multimodal deep learning model to measure body composition using chest radiographs and clinical data". Radiology Advances. 2 (5) umaf035. doi:10.1093/radadv/umaf035. PMC 12560821. PMID 41164313. Retrieved 2025-12-03.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Truveta&oldid=1331228817"